https://www.selleckchem.com/pr....oducts/fezolinetant.
ly, alongside qualitative and health-service colleagues, as retrospective capture risks information loss. These analyses are challenging; many cost factors are difficult to identify, access and measure, and assumptions regarding lifetime of the changes are important. Including implementation costs in CEA might make MSC appear less cost effective, influencing future decisions. Future work will incorporate this implementation cost into the full CEAs of the London Cancer MSC. Not applicable. Not applicable.There is paucity of evidence
Like
Comment
Share
